Recent Updates
Recently added Catalysts

JNJ-99220732

Phase 1

Neoplasms | Small Molecules | Other |Johnson & Johnson|Trials Updated: Nov 17, 2026

JNJ-99220732 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment200

FDA Designations

No designations recorded

JNJ-99220732 clinical trials

JNJ-99220732 · 1 trial · 1 indication

Phase 1 1
NCT07943078A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid TumorsNeoplasms
NOT YET_RECRUITING200 Analytics
PHASE1NOT YET_RECRUITING
A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
NeoplasmsUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Adverse Events (AE) by Severity
Up to 3 years 2 months

An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event.

Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Up to 21 days

A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (\>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities.

Secondary Endpoints

Serum Concentration Time Profile of JNJ-99220732
Up to 3 years 2 months
Maximum Observed Concentration (Cmax) of JNJ-99220732
Up to 3 years 2 months
Trough Concentration (Ctrough) of JNJ-99220732
Up to 3 years 2 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
JNJ-99220732 (Part 1 and Part 2)EXPERIMENTALParticipants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first.

Interventions

NameTypeDescription
JNJ-99220732DRUGJNJ-99220732 will be administered intravenously.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion criteria: \- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (\>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specif...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 17, 2026NCT07943078NEW_TRIAL: changed
LOWNov 17, 2026NCT07943078NEW_TRIAL: changed